Patients that discontinued due to adverse events by tested compound category for phase 2 trials Ν **Proportion** 95%-CI Effect size Antiangiogenesis 4 5.8 (2.4; 13.4)Chemotherapy 17 (4.2; 10.7)6.8 **Immunomodulator** 12 7.8 (5.5; 10.8)

7.3

9.0

1.5

7.5

Test for subgroup differences: p = 0.676

(3.7; 14.0)


(6.6; 12.1)

(0.1; 20.1)

(6.1; 9.2)

40

Effect size (95%–CI)



Prediction interval (2.5; 20.7)

1

64

Vaccine

Overall